Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Gross margin51.3%57%55.2%
Operating margin-2,500.7%-977pp-1,260.8%+1,984pp-1,392.9%+4,756pp-1,498.3%+2,079pp-1,524.1%+1,389pp
Net margin-2,454.6%-940pp-1,238.5%+1,987pp-1,380.7%+4,704pp-1,489.7%+2,043pp-1,514.6%+1,376pp
EBITDA margin-2,380.8%-899pp-1,206.8%+1,960pp-1,343.7%+4,630pp-1,453.6%+1,994pp-1,481.3%+1,326pp
Free cash flow margin-1,409.7%-625.6%-543.2%-563.2%
Returns
Return on assets-94.9%-6.3pp-165.1%-54.8pp-106.5%-49.6pp-101.3%-56.7pp-88.6%-36.7pp
Efficiency
Asset turnover0.0×0.1×+0.1×0.1×+0.1×0.1×+0.1×0.1×0.0×
Liquidity
Current ratio2.5×-1.2×1.3×-0.3×2.8×+2.3×+2.7×3.7×+3.0×
Quick ratio2.5×-1.2×1.2×-0.3×2.7×+2.2×3.9×+2.5×3.7×+2.9×
Cash ratio2.3×-0.9×-0.2×2.4×+2.1×3.7×+2.4×3.2×+2.5×
Leverage
Debt-to-assets0.1×0.0×0.1×0.1×0.1×0.1×
Per Share
Book value per share-$0.31-178%-$1.03-9.9%-$0.29-141%$0.03-98.1%$0.40-71.6%
Valuation
Market capitalization$185.35M+92.3%
Enterprise value$160.03M+113%
Price / sales95.1×+72.5×
EV / sales82.1×+64.4×
Free cash flow yield-14.8%+10.1pp
Earnings yield-25.8%+40.0pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Insight Molecular Diagnostics Inc. Common Stock's profit margins?
Insight Molecular Diagnostics Inc. Common Stock (IMDX) runs a 51.3% gross margin and a -2500.7% operating margin, with a -2454.6% net margin.
Where do Insight Molecular Diagnostics Inc. Common Stock's ratios come from?
Every ratio is computed from Insight Molecular Diagnostics Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.